Loading stock data…
IQV
$186.25+2.56 (+1.39%)
After Hours$183.90-2.35 (-1.26%)· Last close Jun 9
IQVIA Holdings Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IQVIA Holdings Inc. in the Healthcare sector is trading at $186.25. Wall Street consensus targets $228.10 (20 analysts), implying a +22.5% move over the next 12 months. The stock is currently 25% below its 52-week high of $247.05, remaining 4.8% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +22.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$186.25
Potential Downside
0%
Whystock Fair Value$186.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$228.10+22.5%
Range$195.00 – $287.00
Fundamentals
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Techno...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.26%
Volume
Today's trading volume
1.13M
Recent News
Q1 Earnings Roundup: IQVIA (NYSE:IQV) And The Rest Of The Drug Development Inputs & Services Segment
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at IQVIA (NYSE:IQV) and the best and worst performers in the drug development inputs & services industry.
Is IQVIA Holdings Stock Outperforming the Dow?
IQVIA Holdings has outperformed the Dow over the past year, and analysts are highly optimistic about the stock’s prospects.
ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?
ICLR looks cheap at 14.7x forward EPS versus peers, but 2026 guidance calls for lower revenue/EPS and a weak margin starting point.
IQVIA Debt Refinance And EPS Upgrade Reshape Long Term Risk Profile
IQVIA Holdings (NYSE:IQV) has announced a €950 million senior notes offering. The company intends to use the proceeds to refinance existing debt and increase financial flexibility. Management has also revised adjusted earnings per share guidance for 2026 upward. For investors watching IQVIA Holdings at a current share price of $183.45, this new financing move is a key update. The stock is up 4.0% over the past 30 days and 20.4% over the past year, although it is down 18.6% year to date and...
ICLR Earnings Reset: What the Accounting Probe Changed
ICON plc details an accounting restatement, flags control weaknesses, and frames 2026 as a reset year amid mix-driven earnings swings.